摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(2-ethoxyphenyl)-4-(3-pyridinyl)-1,3-thiazol-2-amine

中文名称
——
中文别名
——
英文名称
N-(2-ethoxyphenyl)-4-(3-pyridinyl)-1,3-thiazol-2-amine
英文别名
N-(2-ethoxyphenyl)-4-pyridin-3-yl-1,3-thiazol-2-amine
N-(2-ethoxyphenyl)-4-(3-pyridinyl)-1,3-thiazol-2-amine化学式
CAS
——
化学式
C16H15N3OS
mdl
——
分子量
297.4
InChiKey
CFMJTIHWRFWNKD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    21
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    75.3
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION
    申请人:JACKSON Paul Francis
    公开号:US20120302573A1
    公开(公告)日:2012-11-29
    This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.
    这项发明涉及预防、治疗或改善由MMP9和/或MMP13介导的综合症、紊乱或疾病的方法,包括向需要的受试者施用本说明书示例部分列出的化合物的有效量,或其形式、组合或药物。治疗和/或预防的疾病包括类风湿关节炎。
  • Hedgehog Pathway Antagonists
    申请人:Beachy A. Philip
    公开号:US20070232661A1
    公开(公告)日:2007-10-04
    Aromatic compounds for treating various diseases and pathologies are disclosed. The methods use of such compounds are also provided. Accordingly, the present invention makes available methods and compositions for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function.
  • US8067608B2
    申请人:——
    公开号:US8067608B2
    公开(公告)日:2011-11-29
  • [EN] THIAZOL DERIVATIVES AS PRO -MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DÉRIVÉS DE THIAZOLE EN TANT QU'INHIBITEURS DE PRO-MÉTALLOPROTÉINASES DE MATRICE
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2012162468A1
    公开(公告)日:2012-11-29
    This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a thiazol derivative such as a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.
查看更多